ICL CEO discloses stock option holdings

Q: How many ICL ordinary shares are covered by Elad Aharonson’s stock options?

Elad Aharonson’s options cover multiple blocks of ICL ordinary shares, including 306,748 shares, 737,705 shares, 1,118,290 shares, and 2,308,963 shares. Each block has its own exercise price and expiration date, reflecting separate stock option grants disclosed in the filing.

Q: What are the exercise prices of Elad Aharonson’s ICL stock options?

The filing lists exercise prices of $6.39, $9.39, $5.87, and $6.78 per share for different option grants. Footnotes explain these represent converted prices from NIS using a Bank of Israel exchange rate of $1.00 to NIS 3.149 as of March 27, 2026.

Q: How do Elad Aharonson’s ICL stock options vest over time?

Some options are already fully vested and exercisable, according to the footnotes. Other grants vest in three equal annual installments from April 4, 2024, or in three installments of 37.58%, 37.58% and 24.82% from March 13, 2025, creating a staggered vesting profile.

Q: When do Elad Aharonson’s ICL stock options expire?

The options expire on several dates: June 30, 2026, February 8, 2027, April 4, 2029, and March 13, 2030. Each expiration date applies to a specific grant with its own exercise price and number of underlying ICL ordinary shares.

Q: Are Elad Aharonson’s ICL stock options held directly or through a trustee?

The filing shows the options as direct holdings, and a footnote states that some options are held by a Trustee in the name of the Reporting Person. This indicates beneficial ownership remains with Elad Aharonson despite trustee custody.

ICL Group Ltd. President & CEO Elad Aharonson reported existing holdings of stock options to buy ICL ordinary shares.

Accepted by SEC EDGAR 03/30/2026 - 06:30 PM EDT

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

ICL Group Ltd. President & CEO Elad Aharonson reported existing holdings of stock options to buy ICL ordinary shares. These options cover 306,748 underlying shares at an exercise price of $6.39 per share expiring on June 30, 2026, 737,705 underlying shares at $9.39 expiring on February 8, 2027, 1,118,290 underlying shares at $5.87 expiring on April 4, 2029, and 2,308,963 underlying shares at $6.78 expiring on March 13, 2030. Footnotes state that some options are fully vested and exercisable, while others vest in three annual installments from April 4, 2024 and March 13, 2025, including specified vesting percentages.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Aharonson Elad

Role President & CEO

Type	Security	Shares	Price	Value
Holding	Stock Options (Right to Buy)	--	--	--
Holding	Stock Options (Right to Buy)	--	--	--
Holding	Stock Options (Right to Buy)	--	--	--
Holding	Stock Options (Right to Buy)	--	--	--

Holdings: Stock Options (Right to Buy) — 4,471,706 contracts (Direct)

Footnotes (8)

F1. The stock options are fully vested and exercisable.
F2. The stock options vest in three equal annual installments from the April 4, 2024, grant date.
F3. The stock options vest in three annual installments (37.58%, 37.58%, 24.82%) from the March 13, 2025, grant date.
F4. Represents an exercise price of NIS 20.13, converted to U.S. dollars using the Bank of Israel representative exchange rate of $1.00 to NIS 3.149 as of March 27, 2026.
F5. The options are held by a Trustee in the name of the Reporting Person.
F6. Represents an exercise price of NIS 29.57, converted to U.S. dollars using the Bank of Israel representative exchange rate of $1.00 to NIS 3.149 as of March 27, 2026.
F7. Represents an exercise price of NIS 18.47, converted to U.S. dollars using the Bank of Israel representative exchange rate of $1.00 to NIS 3.149 as of March 27, 2026.
F8. Represents an exercise price of NIS 21.34, converted to U.S. dollars using the Bank of Israel representative exchange rate of $1.00 to NIS 3.149 as of March 27, 2026.

Key Figures

Option grant 1 exercise price: $6.39 per share Option grant 2 exercise price: $9.39 per share Option grant 3 exercise price: $5.87 per share +3 more

6 metrics

Option grant 1 exercise price $6.39 per share Stock options over 306,748 underlying ordinary shares expiring June 30, 2026

Option grant 2 exercise price $9.39 per share Stock options over 737,705 underlying ordinary shares expiring February 8, 2027

Option grant 3 exercise price $5.87 per share Stock options over 1,118,290 underlying ordinary shares expiring April 4, 2029

Option grant 4 exercise price $6.78 per share Stock options over 2,308,963 underlying ordinary shares expiring March 13, 2030

Vesting from April 4, 2024 Three equal annual installments Footnote states options vest in three equal annual installments from April 4, 2024 grant date

Vesting from March 13, 2025 37.58%, 37.58%, 24.82% Footnote states options vest in three annual installments from March 13, 2025 grant date

Key Terms

Stock Options (Right to Buy), Ordinary Shares, exercise price, vest in three equal annual installments, +1 more

5 terms

Stock Options (Right to Buy) financial

"security_title: Stock Options (Right to Buy)"

Ordinary Shares financial

"underlying_security_title: Ordinary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

exercise price financial

"Represents an exercise price of NIS 20.13, converted to U.S. dollars"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in three equal annual installments financial

"The stock options vest in three equal annual installments from the April 4, 2024, grant date."

Trustee financial

"The options are held by a Trustee in the name of the Reporting Person."

A trustee is a person or institution legally appointed to hold and manage assets or enforce an agreement on behalf of other people (beneficiaries). Think of a trustee as a neutral referee or custodian who must act in the beneficiaries’ best interests, follow the trust or contract rules, and handle distributions, recordkeeping and enforcement. Investors care because a trustworthy trustee protects their rights, ensures promised payments or remedies are delivered, and can influence recoveries if things go wrong.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the ICL (ICL) Form 3 filing by CEO Elad Aharonson show?

The Form 3 shows CEO Elad Aharonson’s existing stock option holdings in ICL Group Ltd.. It details four option grants over ICL ordinary shares, including underlying share amounts, exercise prices in U.S. dollars, expiration dates, and vesting schedules described in the footnotes.

How many ICL ordinary shares are covered by Elad Aharonson’s stock options?

Elad Aharonson’s options cover multiple blocks of ICL ordinary shares, including 306,748 shares, 737,705 shares, 1,118,290 shares, and 2,308,963 shares. Each block has its own exercise price and expiration date, reflecting separate stock option grants disclosed in the filing.

What are the exercise prices of Elad Aharonson’s ICL stock options?

The filing lists exercise prices of $6.39, $9.39, $5.87, and $6.78 per share for different option grants. Footnotes explain these represent converted prices from NIS using a Bank of Israel exchange rate of $1.00 to NIS 3.149 as of March 27, 2026.

How do Elad Aharonson’s ICL stock options vest over time?

Some options are already fully vested and exercisable, according to the footnotes. Other grants vest in three equal annual installments from April 4, 2024, or in three installments of 37.58%, 37.58% and 24.82% from March 13, 2025, creating a staggered vesting profile.

When do Elad Aharonson’s ICL stock options expire?

The options expire on several dates: June 30, 2026, February 8, 2027, April 4, 2029, and March 13, 2030. Each expiration date applies to a specific grant with its own exercise price and number of underlying ICL ordinary shares.

Are Elad Aharonson’s ICL stock options held directly or through a trustee?

The filing shows the options as direct holdings, and a footnote states that some options are held by a Trustee in the name of the Reporting Person. This indicates beneficial ownership remains with Elad Aharonson despite trustee custody.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Aharonson Elad

(Last)

(First)

(Middle)

C/O ICL GROUP LTD.

MILLENNIUM TOWER, 23 ARENHA ST.

(Street)

TEL AVIV

6120201

(City)

(State)

(Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
ICL Group Ltd. [ ICL ]

3a. Foreign Trading Symbol
[ICL]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President & CEO

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Options (Right to Buy)	⁽¹⁾	06/30/2026	Ordinary Shares	306,748	$6.39⁽⁴⁾	D⁽⁵⁾
Stock Options (Right to Buy)	⁽¹⁾	02/08/2027	Ordinary Shares	737,705	$9.39⁽⁶⁾	D⁽⁵⁾
Stock Options (Right to Buy)	⁽²⁾	04/04/2029	Ordinary Shares	1,118,290	$5.87⁽⁷⁾	D⁽⁵⁾
Stock Options (Right to Buy)	⁽³⁾	03/13/2030	Ordinary Shares	2,308,963	$6.78⁽⁸⁾	D⁽⁵⁾

Explanation of Responses:

1. The stock options are fully vested and exercisable.

2. The stock options vest in three equal annual installments from the April 4, 2024, grant date.

3. The stock options vest in three annual installments (37.58%, 37.58%, 24.82%) from the March 13, 2025, grant date.

4. Represents an exercise price of NIS 20.13, converted to U.S. dollars using the Bank of Israel representative exchange rate of $1.00 to NIS 3.149 as of March 27, 2026.

5. The options are held by a Trustee in the name of the Reporting Person.

6. Represents an exercise price of NIS 29.57, converted to U.S. dollars using the Bank of Israel representative exchange rate of $1.00 to NIS 3.149 as of March 27, 2026.

7. Represents an exercise price of NIS 18.47, converted to U.S. dollars using the Bank of Israel representative exchange rate of $1.00 to NIS 3.149 as of March 27, 2026.

8. Represents an exercise price of NIS 21.34, converted to U.S. dollars using the Bank of Israel representative exchange rate of $1.00 to NIS 3.149 as of March 27, 2026.

	/s/ Aharonson Elad	03/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR